SUI Group director receives multi-tranche warrant grant

Campbell Kristina Stanier reported disposition transactions in this Form 4 filing.

Rhea-AI Filing Summary

Campbell Kristina Stanier reported disposition transactions in this Form 4 filing.

SUI Group Holdings Ltd. reported that director Kristina Stanier Campbell received a one-time equity grant in the form of warrants for common stock upon her appointment to the board effective July 6, 2026. The grant consists of three warrant tranches for 41,513 underlying shares each with exercise prices of $7.0460, $6.5040 and $5.9620, and one tranche for 83,026 underlying shares at $5.4200, all expiring on July 6, 2031. Each tranche vests in four equal installments: 25% on January 6, 2027, 25% on July 6, 2027, 25% on January 6, 2028 and 25% on July 6, 2028.

Insider Trade Summary

Grant/Award: 207,565 shares

Grant/Award 4 txns

Insider Campbell Kristina Stanier

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Warrant for Common Stock F1, F2	83,026	$0.00	$0.00
Grant/Award	Warrant for Common Stock F1, F2	41,513	$0.00	$0.00
Grant/Award	Warrant for Common Stock F1, F2	41,513	$0.00	$0.00
Grant/Award	Warrant for Common Stock F1, F2	41,513	$0.00	$0.00

Holdings After Transaction: Warrant for Common Stock — 207,565 contracts (Direct)

Footnotes (2)

1. F1. Represents one-time equity grant as part of the Reporting Person's non-management director compensation upon her appointment to the Issuer's Board of Directors, effective July 6, 2026.
2. F2. The warrants vest as follows: 25% of each tranche of the warrants become exercisable on January 6, 2027, 25% of each tranche of the warrants will become exercisable on July 6, 2027, 25% of each tranche of the warrants will become exercisable on January 6, 2028, and 25% of each tranche of the warrants will become exercisable on July 6, 2028.

Key Figures

Warrant tranche shares: 41,513 warrants Warrant tranche exercise price: $7.0460 per share Warrant tranche exercise price: $6.5040 per share +5 more

8 metrics

Warrant tranche shares 41,513 warrants One of three warrant tranches with 41,513 underlying common shares each

Warrant tranche exercise price $7.0460 per share Exercise price for a 41,513-share warrant tranche

Warrant tranche exercise price $6.5040 per share Exercise price for a 41,513-share warrant tranche

Warrant tranche exercise price $5.9620 per share Exercise price for a 41,513-share warrant tranche

Largest warrant tranche shares 83,026 warrants Warrant tranche with 83,026 underlying common shares at $5.4200

Warrant exercise price $5.4200 per share Exercise price for the 83,026-share warrant tranche

Warrant expiration date July 6, 2031 Expiration date for all four warrant tranches granted to the director

Initial vesting date January 6, 2027 First 25% vesting date for each warrant tranche

Key Terms

non-management director compensation, warrants, tranche, vest

4 terms

non-management director compensation financial

"Represents one-time equity grant as part of the Reporting Person's non-management director compensation"

warrants financial

"The warrants vest as follows: 25% of each tranche of the warrants become exercisable"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

tranche financial

"25% of each tranche of the warrants become exercisable on January 6, 2027"

A tranche is one slice of a larger financing or investment that is released, sold, or paid out in separate parts rather than all at once. Investors care because each slice can carry different risk, return and timing—like buying pieces of a cake where some slices are richer or come later—so the specific tranche you hold affects when you get paid and how much you might gain or lose.

vest financial

"The warrants vest as follows: 25% of each tranche of the warrants become exercisable"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SUI Group Holdings (SUIG) report for Kristina Stanier Campbell?

SUI Group Holdings reported a one-time equity grant to director Kristina Stanier Campbell in the form of warrants for common stock upon her July 6, 2026 appointment to the board, structured in four tranches with different exercise prices and a 2031 expiration.

How many SUI Group (SUIG) warrant tranches were granted to the director and at what exercise prices?

The director received four warrant tranches: three tranches each over 41,513 underlying shares with exercise prices of $7.0460, $6.5040 and $5.9620, and one tranche over 83,026 underlying shares with an exercise price of $5.4200, all for common stock.

What is the vesting schedule for the SUI Group (SUIG) director warrant grant?

Each warrant tranche vests in four equal 25% installments: on January 6, 2027, July 6, 2027, January 6, 2028, and July 6, 2028. After these dates, the respective portions of each tranche become exercisable for common stock.

When do the SUI Group (SUIG) director warrants expire?

All four warrant tranches granted to the director have a common expiration date of July 6, 2031. After that date, any unexercised portion of the warrants will no longer be exercisable for SUI Group Holdings common stock.

Was the SUI Group (SUIG) director warrant grant part of management compensation?

The warrants represent a one-time equity grant as part of the reporting person’s non-management director compensation upon appointment to the board, effective July 6, 2026, rather than a management or executive officer compensation package.

Are the SUI Group (SUIG) director warrant transactions reported under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote stating that the director’s warrant grant was made pursuant to a Rule 10b5-1 or other pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/20/2026 - 10:10 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Campbell Kristina Stanier

(Last) (First) (Middle)

C/O SUI GROUP HOLDINGS LTD

1907 WAYZATA BOULEVARD, SUITE 205

(Street)

WAYZATA MINNESOTA 55391

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SUI Group Holdings Ltd. [ SUIG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant for Common Stock	$5.42	07/06/2026		A			83,026(1)	(2)	07/06/2031	Common Stock	83,026	$0	83,026	D
Warrant for Common Stock	$5.962	07/06/2026		A			41,513(1)	(2)	07/06/2031	Common Stock	41,513	$0	41,513	D
Warrant for Common Stock	$6.504	07/06/2026		A			41,513(1)	(2)	07/06/2031	Common Stock	41,513	$0	41,513	D
Warrant for Common Stock	$7.046	07/06/2026		A			41,513(1)	(2)	07/06/2031	Common Stock	41,513	$0	41,513	D

Explanation of Responses:

1. Represents one-time equity grant as part of the Reporting Person's non-management director compensation upon her appointment to the Issuer's Board of Directors, effective July 6, 2026.

2. The warrants vest as follows: 25% of each tranche of the warrants become exercisable on January 6, 2027, 25% of each tranche of the warrants will become exercisable on July 6, 2027, 25% of each tranche of the warrants will become exercisable on January 6, 2028, and 25% of each tranche of the warrants will become exercisable on July 6, 2028.

	/s/ Campbell Kristina Stanier	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)